98%
921
2 minutes
20
Background: This study aimed to evaluate the effectiveness and safety of closed reduction and internal fixation (CRIF) versus closed reduction and external fixation (CREF) in treating tibiofibular fractures, focusing on their impact on bone metabolism and inflammatory responses.
Methods: A retrospective analysis was conducted on the clinical data of 95 patients with tibiofibular fractures, categorised into the CRIF group (CRIFG) and the CREF group (CREFG). Clinical efficacy, Visual Analogue Scale (VAS) scores, serum bone metabolism markers, serum inflammatory cytokines, Generic Quality of Life Inventory-74 (GQOLI-74) scores, and adverse reactions (AR) were compared between the groups.
Results: The total clinical efficacy rates were 80.49% (33/41) in the CRIFG and 85.19% (46/54) in the CREFG (P>0.05). Compared to CRIFG, the CREFG group exhibited significantly lower VAS scores and higher GQOLI-74 scores across all dimensions. Additionally, the CREFG group showed increased levels of serum osteocalcin (BGP), bone alkaline phosphatase (BALP), and N-terminal propeptide of type 1 procollagen (P1NP), along with decreased levels of type I collagen carboxy-terminal peptide b special sequence (b-CTX). Inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-1b, and tumour necrosis factor-a (TNF-a), were significantly lower in the CREFG group. The total AR rate was also lower in CREFG (18.52% vs. 31.71%, P<0.05).
Conclusions: Compared to CRIF, CREF treatment is more effective in reducing pain, enhancing bone metabolism, alleviating inflammatory responses, and improving the overall quality of life (QoL) in patients with tibiofibular fractures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363362 | PMC |
http://dx.doi.org/10.5937/jomb0-55571 | DOI Listing |
Calcif Tissue Int
September 2025
FirmoLab, Fondazione F.I.R.M.O. Onlus and Stabilimento Chimico Farmaceutico Militare (SCFM), 50141, Florence, Italy.
X-linked hypophosphatemia (XLH) is a rare and progressive disease, due to inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene. These pathogenic variants result in elevated circulating levels of fibroblast growth factor 23 (FGF23), responsible for the main clinical manifestations of XLH, such as hypophosphatemia, skeletal deformities, and mineralization defects. However, XLH also involves muscular disorders (muscle weakness, pain, reduced muscle density, peak strength, and power).
View Article and Find Full Text PDFLife Sci
September 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Int J Sport Nutr Exerc Metab
September 2025
Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.
The Union Cycliste Internationale recognizes several mountain biking (MTB) disciplines, including downhill, enduro, cross-country short track, cross-country Olympic, cross-country marathon, and multiday stage racing. Cyclocross is recognized as a separate cycling discipline. Both MTB and cyclocross include cycling on off-road surfaces of varying technicality on specialized bicycles purposed for the respective disciplines.
View Article and Find Full Text PDFJ Bone Joint Surg Am
September 2025
Orthopaedic Department, EpiCURA Hospital, Hainaut, Belgium.
Background: Several studies have investigated the risk of complex regional pain syndrome (CRPS) and its prevention with vitamin C. However, evidence regarding the effectiveness of vitamin C for prevention of CRPS development or recurrence after total knee arthroplasty (TKA) is lacking.
Methods: This retrospective single-center observational cohort study, which utilized propensity-score matching (PSM), was conducted from January 2017 to December 2021.
Eur Arch Paediatr Dent
September 2025
Araçatuba School of Dentistry, São Paulo State University - UNESP, Araçatuba, Brazil.
Purpose: This systematic review provides a critical evaluation, synthesis of the existing literature on isotretinoin's effects on craniomaxillofacial bone.
Methods: Following the PRISMA guidelines and registered in PROSPERO, the review was conducted in August 2024 across various databases. Eligible in vivo studies were analysed for their assessment of isotretinoin's effects on craniomaxillofacial bone.